{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:55:59Z","timestamp":1771955759305,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Center for Fertility Research and Education\u2014Extend Fertility Medical Practice"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Does GnRH-agonist trigger offer similar maturity rate (MR) in low and normal responders compared to high responders in women undergoing planned oocyte cryopreservation, for whom even a small risk of ovarian hyperstimulation syndrome (OHSS) may not be acceptable?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>GnRH-agonist is an appropriate choice for final maturation of oocytes in planned oocyte cryopreservation, regardless of response to stimulation or risk of ovarian hyperstimulation syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Numerous studies have demonstrated the utility of GnRH-agonist trigger for the prevention of ovarian hyperstimulation in high-responder in vitro fertilization cycles. Limited data exist supporting its use in normal or low responders, or in non-infertile women undergoing planned oocyte cryopreservation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>Retrospective cohort study of 1189 subjects including all planned oocyte cryopreservation cycles performed at a large, single center, oocyte cryopreservation program from April 2016 to December 2018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>A total of 1680\u00a0cycles were included in the study. A total of 57.1% (959\/1680) utilized GnRH-agonist for trigger. Demographic and clinical data were collected from the medical record. Maturation rate was calculated for the entire cohort, and by trigger type, using the quotient of Metaphase II (MII) oocytes and retrieved oocytes. A sub-cohort of GnRH-agonist trigger cycles were categorized by peak estradiol (E2) levels and maturation rates compared between groups. Associations were made using Student\u2019s t test, ANOVA, Mann\u2013Whitney U and Kruskal\u2013Wallis, where appropriate. A sample size calculation for 90% power with a significance of 5% to detect non-inferiority of &amp;lt;0.05 from a 0.75 maturity rate between subjects with E2\u2009&amp;gt;\u20093000\u00a0pg\/mL and E2\u2009&amp;lt;\u20093000\u00a0pg\/mL demonstrated the need for at least 116\u00a0cycles per group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Mean MR was 0.71\u2009\u00b1\u20090.19 overall, and 0.73\u2009\u00b1\u20090.18 in the sub-cohort of GnRH-agonist trigger cycles. A total of 611\u00a0cycles (63.7%) had peak E2\u2009&amp;lt;\u20093000, and 331 (34.5%) had E2\u2009&amp;gt;\u20093000. No significant difference in maturity rate was noted between cycles with E2 levels &amp;gt;3000\u00a0pg\/mL and &amp;lt;3000\u00a0pg\/mL (0.72\u2009\u00b1\u20090.19 vs. 0.74\u2009\u00b1\u20090.14, P\u2009=\u20090.18), confirming the non-inferiority of maturity rates with GnRH-agonist triggers in cycles with peak E2\u2009&amp;lt;\u20093000\u00a0pg\/mL. While lower mean oocytes retrieved and mean MII oocytes were associated with lower peak E2 levels, maturity rate did not significantly differ amongst E2 level groups. Cycles with E2\u2009&amp;lt;\u20091000\u00a0pg\/mL had lower MR irrespective of trigger type.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The retrospective nature cannot entirely exclude selection biases, confounding factors or additional variables that could not be accounted for or were not collected by the electronic medical record. Given the nature of planned oocyte cryopreservation, studies of ongoing pregnancy rates and birth outcomes will naturally be delayed. Lastly, the study population was limited to women undergoing planned oocyte cryopreservation; therefore, the results may not be generalizable to women undergoing in vitro fertilization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>This is the first study specifically comparing the efficacy of GnRH-agonist in patients at lower risk for OHSS to those at high risk, as well the first study evaluating GnRH-agonist\u2019s efficacy specifically in planned oocyte cryopreservation cycles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>Study support provided by departmental funds from the Center for Fertility Research and Education\u2014Extend Fertility Medical Practice. BLM discloses personal fees from Ferring Pharmaceuticals and Merck KgAA, unrelated to the submitted work. C.S., M.G., L.R. and J.K. have nothing to disclose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deaa042","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T20:16:01Z","timestamp":1582661761000},"page":"1054-1060","source":"Crossref","is-referenced-by-count":11,"title":["The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation"],"prefix":"10.1093","volume":"35","author":[{"given":"Bat-Sheva L","family":"Maslow","sequence":"first","affiliation":[{"name":"Center for Fertility Research and Education, Extend Fertility, 200 West 57th Street, Suite 1101 New York, NY 10019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Guarnaccia","sequence":"first","affiliation":[{"name":"Center for Fertility Research and Education, Extend Fertility, 200 West 57th Street, Suite 1101 New York, NY 10019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Stefanacci","sequence":"first","affiliation":[{"name":"Center for Fertility Research and Education, Extend Fertility, 200 West 57th Street, Suite 1101 New York, NY 10019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Ramirez","sequence":"first","affiliation":[{"name":"Center for Fertility Research and Education, Extend Fertility, 200 West 57th Street, Suite 1101 New York, NY 10019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua U","family":"Klein","sequence":"first","affiliation":[{"name":"Center for Fertility Research and Education, Extend Fertility, 200 West 57th Street, Suite 1101 New York, NY 10019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"2020052910300413900_ref1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.fertnstert.2018.02.003","article-title":"Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter?","volume":"109","author":"Benadiva","year":"2018","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref2","first-page":"1","article-title":"Risk of ovarian torsion is reduced in GnRH agonist triggered freeze-all cycles: a retrospective cohort study","author":"Berkkanoglu","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"2020052910300413900_ref3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.fertnstert.2014.05.030","article-title":"Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization","volume":"102","author":"Budinetz","year":"2014","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.fertnstert.2015.01.012","article-title":"Introduction: gonadotropin-releasing hormone agonist triggering of final follicular maturation for in vitro fertilization","volume":"103","author":"Casper","year":"2015","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.fertnstert.2016.06.013","article-title":"Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response","volume":"106","author":"Chang","year":"2016","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.fertnstert.2018.08.027","article-title":"Planned oocyte cryopreservation for women seeking to preserve future reproductive potential: an ethics committee opinion","volume":"110","author":"Daar","year":"2018","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/OGX.0000000000000432","article-title":"Gonadotropin-releasing hormone-agonist triggering and a freeze-all approach: the final step in eliminating ovarian hyperstimulation syndrome?","volume":"72","author":"Davenport","year":"2017","journal-title":"Obstet Gynecol Surv"},{"key":"2020052910300413900_ref8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.fertnstert.2009.10.034","article-title":"Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting","volume":"94","author":"DiLuigi","year":"2010","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.repbio.2017.01.004","article-title":"Gonadotropin-releasing hormone agonist (GnRHa) trigger - state of the art","volume":"17","author":"Dosouto","year":"2017","journal-title":"Reprod Biol"},{"key":"2020052910300413900_ref10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbmo.2015.12.007","article-title":"GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis","volume":"32","author":"Engmann","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"2020052910300413900_ref11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.fertnstert.2013.05.028","article-title":"Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"100","author":"Fatemi","year":"2013","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/humupd\/dmi045","article-title":"GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis","volume":"12","author":"Griesinger","year":"2006","journal-title":"Hum Reprod Update"},{"key":"2020052910300413900_ref14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fendo.2017.00116","article-title":"GnRH agonist trigger and LH activity luteal phase support versus hCG trigger and conventional luteal phase support in fresh embryo transfer IVF\/ICSI cycles-a systematic PRISMA review and meta-analysis","volume":"8","author":"Haahr","year":"2017","journal-title":"Front Endocrinol"},{"key":"2020052910300413900_ref15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10815-017-1111-3","article-title":"Frozen blastocyst transfer outcomes in immediate versus delayed subsequent cycles following GnRH agonist or hCG triggers","volume":"35","author":"Kaye","year":"2018","journal-title":"J Assist Reprod Genet"},{"key":"2020052910300413900_ref16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0974-1208.192056","article-title":"Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: a randomized control trial","volume":"9","author":"Krishna","year":"2016","journal-title":"J Hum Reprod Sci"},{"key":"2020052910300413900_ref17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.fertnstert.2011.04.050","article-title":"Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist","volume":"96","author":"Kummer","year":"2011","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rbmo.2017.09.014","article-title":"GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?","volume":"36","author":"Lawrenz","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2020052910300413900_ref19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.fertnstert.2015.06.011","article-title":"Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles","volume":"104","author":"Meyer","year":"2015","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref20","first-page":"CD012103","article-title":"Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews","volume":"1","author":"Mourad","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2020052910300413900_ref21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.fertnstert.2017.06.027","article-title":"Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation","volume":"108","author":"Pereira","year":"2017","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref22","volume-title":"Power Calculator for Continuous Outcome Non-inferiority Trial","author":"Sealed Envelope Ltd.","year":"2012"},{"key":"2020052910300413900_ref23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.fertnstert.2019.03.040","article-title":"Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin","volume":"112","author":"Thorne","year":"2019","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rbmo.2017.03.017","article-title":"Cumulative live birth rate after GnRH agonist trigger and elective cryopreservation of all embryos in high responders","volume":"35","author":"Vlaisavljevi\u0107","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2020052910300413900_ref25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.fertnstert.2015.10.014","article-title":"Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study","volume":"105","author":"Vuong","year":"2016","journal-title":"Fertil Steril"},{"key":"2020052910300413900_ref26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5935\/1518-0557.20170036","article-title":"Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial","volume":"21","author":"Zarcos","year":"2017","journal-title":"JBRA Assist Reprod"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/35\/5\/1054\/33322295\/deaa042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/35\/5\/1054\/33322295\/deaa042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T14:30:37Z","timestamp":1590762637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/35\/5\/1054\/5836964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaa042","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]}}}